April 01, 2021 + Jessica Di Palo
3 Min read
Today, MTIP AG, a Basel-based private equity firm that invests in healthtech companies, is pleased to announce that it has completed the first closing of its Fund II. The growth capital fund secured EUR 130m and is well on track towards the target fund size of EUR 200m.
MTIP FUND II, SCSp is MTIP’s second healthtech fund, designed to provide growth capital and build on the healthtech investment thesis of its successful predecessor. With a target size of EUR 200m the fund invests in digital health and connected medical device companies, based primarily in Europe, that offer differentiated solutions for a rapidly evolving healthcare environment.
MTIP’s second fund executed a strong first closing securing EUR 130m. The capital was raised by different investors comprising mainly institutional investors, pension funds, family offices, hospitals, and foundations. The company is especially proud to work together with the European Investment Fund (EIF) as an anchor investor. EIF’s Chief Executive Alain Godard said: “Digital health is a field of both great potential and high priority for patients and healthcare providers alike. With a market estimated to continuous growing, healthtech is at the center of major on-going and upcoming innovations. MTIP’s fund strategy fits with EIF’s ambition of financing the vital growth segment of the European Venture Capital ecosystem, which is largely underfunded and overly dependent on non-European investors for larger investments. The EIF is pleased to support MTIP and tackle two major gaps in the European market – digital health and growth capital.”
“This closing is an enormously important milestone in our company history, and we are particularly pleased to have overachieved our expectations – even during a pandemic. Our Fund II has already added three stellar investments to its portfolio with more to come in the near future. This creates a strong momentum towards the final close”, emphasizes Dr. Christoph Kausch, Managing Partner of MTIP. “We are pleased to have onboarded existing investors as well as new limited partners for the first closing of our newest Fund and are grateful for the support and confidence they have shown towards our investment strategy and our mission to empower innovation that improves lives”, he continues.
MTIP is the first pure play pan-European healthtech investor and has already executed three very well distinguished investments with its newest fund. The first investment was carried out in Oviva, a digital nutritional therapy platform that offers both face-to-face sessions and remote support for clients from dietitians via smartphone app. The second one in Trialbee, a digital platform for patient recruitment and retention for clinical trials. And finally, Koa Health, that delivers mental health support that adapts to individuals’ unique circumstances. The Fund continues to see a unique flow of new investment opportunities, enhanced by the firm’s extensive network, its leading role in Europe, and the strength of its strategy.
MTIP is a pan-European healthtech growth capital investor, based in Basel Switzerland. We invest in digital health and digitally connected medical device companies, with offerings that provide clear health-related economic benefits. Our entrepreneurial investment team, which has complementary private equity skills and exceptional deal-making capabilities, actively works with our portfolio companies to boost growth. MTIP efficiently deploys capital to unlock value and generate attractive returns for our investors. Visit www.mtip.ch for more information.
Pioneering the use of machine learning algorithms to turbo-charge drug development
Intelligencia revolutionizes drug development
The psychology of decision making
What makes a good investor?
Revolutionizing medical triage with artificial intelligence
Mediktor's solution for medical triage
MTIP Closes Second Healthtech Growth Fund Above Target With $250M of Commitments
MTIP Fund II is closed!
Cynerio Now! – A new IoT cybersecurity solution for small hospitals and clinics
Cynerio's new product Cynerio Now!
MTIP invests in Mediktor
New investment in Mediktor
SFDR Art. 8 or Art. 9? What’s the difference?
SFDR: getting the terminology right
MTIP participates in Oviva’s new $80m Series C funding
Oviva raises $80 million financing round
MTIP invests in Intelligencia to reduce the risk of clinical research through artificial intelligence
MTIP's new investment in Intelligencia
Private Equity 101: Part one – Glossary
Are you new to the healthtech space?
Leading brands revolutionize care journeys with Lumeon
How Lumeon orchestrates care journey
Trialbee – our hero in patient matching and recruiting for clinical trials
Trialbee - patient matching and recruiting
Digital healthcare: patient-first?
Digital Healthcare Report 2021 in collaboration with Dealroom and INKEF Capital
SFDR – How does MTIP approach the EU’s Sustainable Disclosure Regulation?
New SFDR obligations
MTIP Announces Strong First Closing of Fund II to drive Healthtech Innovation
First Closing of Fund II
How to pitch to a healthtech Investor
MTIP invests in Koa Health to make mental health treatment more accessible
New investment in Koa Health
MTIP scored fantastic grades in the UNPRI assessment report of 2020
UNPRI Report grades 2020
4 Health VCs Share Their Business Priorities and What is Next
MTIP invests in Trialbee
New investment in Trialbee
TytoCare closes $50 million round as the demand for telehealth accelerates
TytoCare closes new round
The digital healthtech sector is expanding – and so are we!
Two new empolyees start in April
MTIP has sucessfully exited Blueprint Genetics
Blueprint exit January 2020
New MTIP investment in Oviva
New investment in Oviva
Whitepaper: A positive prognosis for the future of healthtech
Our first Whitepaper